SUNRISE, Fla., Feb. 6, 2009 (GLOBE NEWSWIRE) -- Bioheart, Inc. (Nasdaq:BHRT), a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases, announced today that Howard J. Leonhardt, chief executive officer and chairman, will provide an update of corporate activities at the 11th Annual BIO CEO & Investor Conference on Monday, February 9, 2009, at 11:00 a.m. Eastern time. The presentation is being held at the Waldorf-Astoria in New York City.
Now in its eleventh year, the BIO CEO & Investor Conference is the largest independent investor conference focused on publicly traded biotechnology companies. Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information, visit http://www.ceo.bio.org/opencms/ceo/2009/index.jsp.
About Bioheart, Inc.
Bioheart, Inc. (Nasdaq:BHRT) is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient's quality of life and reduce health care costs and hospitalizations. Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(r), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins. For more information on Bioheart, visit www.bioheartinc.com.
MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc.